CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia

Authors

  • Lei-Ming Cao Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Ya-Lan Zhou Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China https://orcid.org/0000-0002-7059-8277
  • Robert Peter Gale Department of Immunology and Inflammation, Centre for Haematology, Imperial College of Science, Technology and Medicine, London, UK
  • Ya-Zhen Qin Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Li-Xin Wu Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Ming-Yue Zhao Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Xiao-Su Zhao Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Yu-Hong Chen Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Yu Wang Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Hao Jiang Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Qian Jiang Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Ying-Jun Chang Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Yan-Rong Liu Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Lan-Ping Xu Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Xiao-Hui Zhang Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
  • Xiao-Jun Huang Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Academy for Advanced Interdisciplinary Studies, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.
  • Guo-Rui Ruan Peking University Institute of Hematology, Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

DOI:

https://doi.org/10.17305/bb.2023.9034

Keywords:

Acute lymphoblastic leukaemia (ALL), relapse, measurable residual disease (MRD), cysteine and glycine-rich protein 2 (CSRP2), multi-parameter flow cytometry (MPFC)

Abstract

Quantification of measurable residual disease (MRD) correlates with the risk of leukaemia recurrence in adults with B-cell acute lymphoblastic leukaemia (ALL). However, it remains unknown whether collecting data on cysteine and glycine-rich protein 2 (CSRP2) transcript levels, after completing the second course of consolidation, improves prognosis prediction accuracy. A total of 204 subjects with B-cell ALL were tested for CSPR2 transcripts after completing the second course of consolidation using quantitative real-time polymerase chain reaction (qRT-PCR) and divided into high (N = 32) and low (N = 172) CSRP2 expression cohorts. In multivariable analyses, subjects with high expression of CSRP2 had a higher 5-year cumulative incidence of relapse (CIR) (Hazard Ratio [HR] = 2. 57 [1.38, 4.76]; P = 0.003), lower 5-year relapse-free survival (RFS) (HR = 3.22 [1.75, 5.93]; P < 0.001) and overall survival (OS) (HR = 4.59 [2.64, 7.99]; P < 0.001) in the whole cohort, as well as in the multiparametric flow cytometry (MPFC) measurable residual disease (MRD)- negative cohort (for CIR, HR = 2.70 [1.19, 6.12]; for RFS, HR = 4.37 [1.94, 9.85]; for OS, HR = 4.90 [2.43, 9.90];  P < 0.05). Prognostic analysis showed that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could significantly improve the prognosis of patients with high CSRP2 transcript levels (allo-HSCT vs chemotherapy: 5-year CIR, 52% vs 91%; RFS, 41% vs 9%; OS, 38% vs 20%; P < 0.05). Our data indicates that incorporating data from CSPR2 transcript levels to the MRD-testing at the end of the second course of consolidation therapy enhances prognosis prediction accuracy in adults with B-cell ALL.

Downloads

Download data is not yet available.
CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia

Published

2023-05-14

How to Cite

1.
Cao L-M, Zhou Y-L, Gale RP, Qin Y-Z, Wu L-X, Zhao M-Y, Zhao X-S, Chen Y-H, Wang Y, Jiang H, Jiang Q, Chang Y-J, Liu Y-R, Xu L-P, Zhang X-H, Huang X-J, Ruan G-R. CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia. Biomol Biomed [Internet]. 2023May14 [cited 2023May30];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/9034

Issue

Section

Translational and Clinical Research